Metgli 1mg/500mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The combination therapy offers complementary mechanisms, making it effective for patients inadequately controlled on monotherapy. Metgli 1mg/500mg Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is important to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and conditions associated with hypoxia. Regular monitoring of renal function and lactic acid levels is recommended during Metformin therapy to prevent rare but serious complications such as lactic acidosis. This combination provides a convenient and effective option for improved glycemic control in type 2 diabetes.